

Electronic Supplementary Information (ESI)

**Design, synthesis and evaluation of a myricetin and nobiletin hybrid compound
for alleviating hyperuricemia based on metabolomics and gut microbiota**

Yan Li,^{‡abc} Liu-Yang Pu,^{‡ac} Yayun Li,^d Guanbao Zhu^e and Zhengzhi Wu^{*abc}

^a Shenzhen Institute of Translational Medicine, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen 518035, China

^b Wu Zhengzhi Academician Workstation, NingBo College of Health Sciences, NingBo 315800, China

^c Shenzhen Institute of Geriatrics, Shenzhen 518035, China

^d Hunan University of Chinese Medicine, Changsha 410208, China

^e Guangxi University of Chinese Medicine, Nanning 530200, China


* Correspondence: szwzz001@163.com

‡ These authors contributed equally to this work.


Table of Contents

¹H NMR and ¹³C NMR spectra for compound 4	2
¹H NMR and ¹³C NMR spectra for compound 6	3
¹H NMR and ¹³C NMR spectra for myricetin-nobiletin hybrid (MNH)	4
Venn diagram and clustering heatmap	5


¹H NMR and ¹³C NMR spectra for compound 4



¹H NMR and ¹³C NMR spectra for compound 6



¹H NMR and ¹³C NMR spectra for myricetin-nobiletin hybrid (MNH)



Venn diagram and clustering heatmap




Fig. S1 Effects of MNH on serum metabonomic profiling. (A-B) Venn diagram of the three groups; (C-D) clustering heatmap analysis of the three groups.